Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center study

Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center study

Abstract Background Trastuzumab and fulvestrant combination therapy is one of the treatment options for patients with hormone receptor- and human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer; however, there are limited studies evaluating the efficacy of this combinatio...

Full description

Bibliographic Details
Main Authors: Yukinori Ozaki, Yosuke Aoyama, Jun Masuda, Lina Inagaki, Saori Kawai, Tomoko Shibayama, Tetsuyo Maeda, Mami Kurata, Kazuyo Yoshida, Sumito Saeki, Mari Hosonaga, Ippei Fukada, Fumikata Hara, Takayuki Kobayashi, Kokoro Kobayashi, Satoshi Miyake, Toshimi Takano, Takayuki Ueno, Shinji Ohno
Format: Article
Language:English
Published: BMC 2022-01-01
Series:BMC Cancer
Subjects:
Trastuzumab
Fulvestrant
Hormone receptor-positive HER2-positive breast cancer
Online Access:https://doi.org/10.1186/s12885-021-09128-1

Internet

https://doi.org/10.1186/s12885-021-09128-1

Similar Items